Document is current
Any future updates will be listed below
-
Authors
Tziortzouda, Paraskevi https://orcid.org/0000-0002-6969-8158
Steyaert, Jolien https://orcid.org/0000-0001-5587-706X
Scheveneels, Wendy
Sicart, Adria https://orcid.org/0009-0004-6102-9381
Stoklund Dittlau, Katarina https://orcid.org/0000-0003-2776-2892
Barbosa Correia, Adriana Margarida
Burg, Thibaut https://orcid.org/0000-0002-8788-2936
Pal, Arun
Hermann, Andreas https://orcid.org/0000-0002-7364-7791
Van Damme, Philip https://orcid.org/0000-0002-4010-2357
Moens, Thomas G. https://orcid.org/0000-0002-4783-6257
Van Den Bosch, Ludo https://orcid.org/0000-0003-0104-4067
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (11C7623N)
- License Information
-
More Information
Article History
Received: 20 October 2023
Revised: 22 December 2023
Accepted: 11 January 2024
First Online: 16 February 2024
Declarations
:
: LVDB is head of the Scientific Advisory Board of Augustine Therapeutics (Leuven, Belgium) and is also part of the Investment Advisory Board of Droia Ventures (Meise, Belgium).
